{"organizations": [], "uuid": "b0ffa643a1582f221ef0ef3ee49eb16aa7881edd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180111.html", "section_title": "Archive News &amp; Video for Thursday, 11 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aradigm-fda-advisory-committee-did/brief-aradigm-fda-advisory-committee-did-not-recommend-approval-for-linhaliq-idUSFWN1P60WO", "country": "US", "domain_rank": 408, "title": "BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.921, "site_type": "news", "published": "2018-01-12T06:06:00.000+02:00", "replies_count": 0, "uuid": "b0ffa643a1582f221ef0ef3ee49eb16aa7881edd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aradigm-fda-advisory-committee-did/brief-aradigm-fda-advisory-committee-did-not-recommend-approval-for-linhaliq-idUSFWN1P60WO", "ord_in_thread": 0, "title": "BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq", "locations": [], "entities": {"persons": [{"name": "linh", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "fda advisory committee did not recommend approval for linhaliq", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "aradigm corp", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "fda adac", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "adac", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "aradigm", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 11 (Reuters) - Aradigm Corp:\n* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​\n* ARADIGM CORP - ‍FDA HAS SET A PDUFA ACTION DATE OF JANUARY 26, 2018 FOR COMPLETION OF ITS REVIEW OF LINHALIQ​\n* ARADIGM CORP - ‍FDA ADAC DID NOT RECOMMEND APPROVAL FOR LINHALIQ AS A TREATMENT FOR NCFBE PATIENTS WITH CHRONIC LUNG PSEUDOMONAS AERUGINOSA INFECTIONS​\n* ARADIGM - ADAC VOTED 12 “NO” TO 3 “YES”, 1 ABSTENTION, ON QUESTION OF CO‘S PROVISION OF EVIDENCE OF SAFETY & EFFICACY OF CIPROFLOXACIN DISPERSION Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-12T06:06:00.000+02:00", "crawled": "2018-01-12T18:33:33.006+02:00", "highlightTitle": ""}